^
ER positive + PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
Gynecol Oncol - 2 weeks
PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
Gynecol Oncol - 2 weeks
ER positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
Gynecol Oncol - 2 weeks
PD-L1 overexpression
Soft Tissue Sarcoma
camrelizumab
Sensitive: C4 – Case Studies
Front Oncol - 2 weeks
ETV6-NTRK3 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: C4 – Case Studies
J Pediatr Hematol Oncol - 3 weeks
KIT positive
GIST
imatinib
Sensitive: A1 - Approval
PDGFRA D842V
GIST
avapritinib
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
olaratumab
Sensitive: A1 - Approval
NTRK3 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
NTRK2 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
NTRK1 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
No biomarker
GIST
sunitinib
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
trabectedin
Sensitive: A1 - Approval
No biomarker
Liposarcoma
eribulin mesylate
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
pazopanib
Sensitive: A1 - Approval
No biomarker
Leiomyosarcoma
trabectedin
Sensitive: A1 - Approval
No biomarker
Liposarcoma
trabectedin
Sensitive: A1 - Approval
No biomarker
GIST
ripretinib
Sensitive: A1 - Approval
PDGFRA exon 18 mutation
GIST
avapritinib
Sensitive: A1 - Approval
No biomarker
Fibrosarcoma
imatinib
Sensitive: A1 - Approval
No biomarker
Kaposi Sarcoma
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
No biomarker
Kaposi Sarcoma
pomalidomide
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
tazemetostat
Sensitive: A1 - Approval
No biomarker
Ewing Sarcoma
dactinomycin
Sensitive: A1 - Approval
No biomarker
Rhabdomyosarcoma
dactinomycin
Sensitive: A1 - Approval
No biomarker
Osteosarcoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
No biomarker
Osteosarcoma
ADX-2191
Sensitive: A1 - Approval
No biomarker
GIST
regorafenib
Sensitive: A1 - Approval
KIT expression
GIST
imatinib
Sensitive: A1 - Approval
No biomarker
Sarcoma
AD
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
ifosfamide + epirubicin + mesna
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
AIM
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
regorafenib
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
IE
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
IE
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
IE
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
VC
Sensitive: A2 - Guideline
NTRK3 fusion
Soft Tissue Sarcoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
GT
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
GT
Sensitive: A2 - Guideline
NTRK2 fusion
GIST
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GIST
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GIST
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Sarcoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Sarcoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive: A2 - Guideline
NTRK2 fusion
Sarcoma
entrectinib
Sensitive: A2 - Guideline
TMB-H
Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Sarcoma
fulvestrant
Sensitive: A2 - Guideline
No biomarker
Sarcoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
No biomarker
Sarcoma
ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Sarcoma
gemcitabine + dacarbazine
Sensitive: A2 - Guideline
No biomarker
Sarcoma
gemcitabine + vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Sarcoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Sarcoma
epirubicin
Sensitive: A2 - Guideline
No biomarker
Sarcoma
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Sarcoma
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Sarcoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Sarcoma
trabectedin
Sensitive: A2 - Guideline
No biomarker
Sarcoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
VAC
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
ifosfamide
Sensitive: A2 - Guideline
NTRK3 fusion
GIST
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Fibrosarcoma
pembrolizumab
Sensitive: A2 - Guideline
NTRK2 fusion
GIST
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GIST
larotrectinib
Sensitive: A2 - Guideline
No biomarker
GIST
cabozantinib tablet
Sensitive: A2 - Guideline
PDGFRA exon 18 mutation
GIST
imatinib
Sensitive: A2 - Guideline
No biomarker
GIST
imatinib
Sensitive: A2 - Guideline
PDGFRA D842V
GIST
dasatinib
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
PGR positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
NTRK1 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
gemcitabine + dacarbazine
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
cediranib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
sunitinib
Sensitive: A2 - Guideline
ALK translocation
Soft Tissue Sarcoma
crizotinib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
regorafenib
Sensitive: A2 - Guideline
No biomarker
Leiomyosarcoma
eribulin mesylate
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
melphalan + busulfan
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
ifosfamide + cyclophosphamide oral + etoposide IV + topotecan
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
temozolomide + irinotecan
Sensitive: A2 - Guideline
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide oral + etoposide IV + vincristine
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
gemcitabine + docetaxel + cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cyclophosphamide oral + regorafenib
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
sorafenib + cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
carboplatin + cyclophosphamide oral + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
carboplatin + cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cyclophosphamide oral + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
gemcitabine + docetaxel + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
carboplatin + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
carboplatin + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cisplatin + ifosfamide + methotrexate + SGN-15
Sensitive: A2 - Guideline